st101
Small moleculeexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2009 (NCT00842816)
Timeline
Indications
Mechanism of action
DDIT3 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- st101
- st101
- st-101
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04478279 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2020 | Sapience Therapeutics, Union Therapeutics |
| NCT01332695 | Phase 2 | Apr 1, 2011 | Sonexa Therapeutics, Inc. |
| NCT00842673 | Phase 2 | Feb 1, 2009 | Sonexa Therapeutics, Inc. |
| NCT00842816 | Phase 2 | Feb 1, 2009 | Sonexa Therapeutics, Inc. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sonexa Therapeutics, Inc. | For profit | 3 | 3 | 1 | 2009 |
| Sapience Therapeutics | For profit | 1 | 1 | 1 | 2020 |
| Union Therapeutics | For profit | 1 | 0 | 1 | 2020 |
3 organizations
Page 1 / 1